Although major diabetes prevention trials show lifestyle intervention delays the onset of type 2 diabetes in persons with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) is typically used in the real world as a more convenient way to identify eligible persons. Such practice includes many without IGT but excludes many with IGT who could benefit from intervention programs. DQDPOS is a long-term follow-up of the Da Qing Diabetes Prevention study, a randomized clinical trial to assess the efficacy of lifestyle intervention to prevent type 2 diabetes in persons with IGT in Da Qing China. We compared the effect of the intervention in those with baseline fasting plasma glucose (FPG) levels of <100 (“normal”, n=287,49.8%) vs. 100-139mg/dl (IFG, n=289,50.2%). Lifestyle intervention reduced diabetes incidence substantially and to a similar extent in both groups at the end of the 6-year intervention and throughout the 30 years of follow-up (hazard ratios 0.50-0.67) (Table). Our results indicate that although using only IFG to identify candidates for lifestyle intervention programs might achieve similar efficacy, its use alone will exclude large numbers of people with IGT but without IFG, who otherwise would benefit from lifestyle interventions.
Q. Gong: None. P. Zhang: None. J. Wang: None. Y. Chen: None. Y. An: None. X. Feng: None. Y.J. Cheng: None. J. Ma: None. P.H. Bennett: Advisory Panel; Self; World Health Organization. Stock/Shareholder; Self; Eli Lilly and Company, Pfizer Inc., Unilever, UnitedHealth Group. Other Relationship; Self; American Diabetes Association, European Association for the Study of Diabetes, European Diabetic Nephropathy Study Group, International Diabetes Federation, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. G. Li: None.